SCHEMBL206718

SCHEMBL206718

OC1CCN(c2ccncc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHKA P35790 1/20 0.59
ADRB2 P07550 1/20 0.53
NCF1 P14598 1/20 0.53
PLD1 Q13393 1/20 0.53
MAPT P10636 2/20 0.48
KDM1A O60341 1/20 0.45
MAOB P27338 1/20 0.45
HRH3 Q9Y5N1 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
LSS P48449 2/20 0.43
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227052 0.88 CHKA (0.50) CHKAADRB2NCF1PLD1MAPT
SCHEMBL7954968 0.88 CHKA (0.50) CHKAADRB2NCF1PLD1MAPT
SCHEMBL6403521 0.88 CHKA (0.50) CHKAADRB2NCF1PLD1MAPT
SCHEMBL4711666 0.81 CHKA (0.61) CHKAADRB2NCF1PLD1KDM1A
SCHEMBL28112415 0.79 CHKA (0.80) CHKAADRB2NCF1PLD1MAPT
SCHEMBL4703601 0.79 CHKA (0.59) CHKAADRB2NCF1PLD1KDM1A
SCHEMBL4712014 0.79 CHKA (0.59) CHKAADRB2NCF1PLD1MAPT
SCHEMBL223203 0.79 CHKA (0.59) CHKAADRB2NCF1PLD1KDM1A
SCHEMBL48910 0.79 CHKA (0.59) CHKAADRB2NCF1PLD1MAPT
SCHEMBL1648623 0.79 CHKA (0.53) CHKAADRB2NCF1PLD1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5058999-A None JP disclosed
EP-1925611-B1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO CO LTD (JP) 2016-04-13 EP disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
CN-102153544-A Preparation method and application of novel tyrosine kinase inhibitors SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD 2011-08-17 CN disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
US-20100093785-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-15 US disclosed
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM DAIICHI PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
EP-0691959-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-17 EP disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 EP disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed
WO-1994022834-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed
US-5300515-A Cognition activators for brain disorders; alzheimer*s disease KYORIN PHARMACEUTICAL CO., LTD. (JP) 1994-04-05 US disclosed
JP-H0558999-A CARBAMIC ACID DERIVATIVE AND ITS PRODUCTION KYORIN PHARMACEUT CO LTD 1993-03-09 JP disclosed
EP-0497303-A2 Carbamic acid derivatives and method for preparing the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
US-5057528-A AMINO-PYRIDINE COMPOUNDS USEFUL AS ANTI-ARRHYTHMIC AGENTS PFIZER INC. (US) 1991-10-15 US disclosed
US-4968704-A PROLONG DURATION OF ACTION POTENTIAL IN CARDIAC MUSCLE AND CONDUCTING TISSUE PFIZER INC. (US) 1990-11-06 US disclosed
EP-0359389-A1 Antiarrhythmic agents Pfizer Limited (GB) 1990-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL CHKA 3371/4885ADRB2 3336/4885NCF1 2434/4885
US-20100093785-A1 DIAMINE DERIVATIVES C9, C1S, C1R CHKA 4547/4885ADRB2 3255/4885NCF1 1302/4885
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM C1R, C9, F2 CHKA 4404/4885ADRB2 2687/4885NCF1 2012/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 CHKA 3189/4885ADRB2 4040/4885NCF1 381/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R CHKA 4596/4885ADRB2 3687/4885NCF1 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.